It has been reported that cisplatin treatment enriches NOTCH1 and CD133-expressing lung cancer stem-like cells from H460 and H661, induce DNA damage responses, and upregulate ABC drug transporters which in turn, increases cross-resistance to other chemotherapeutics (doxorubicin and paclitaxel). This evidence concerns the gene PROM1 and lung carcinoma.